Rare diseases
Investigational molecules
Locations
Study on the Safety and Dosage of GD2IL18CART for Patients with Relapsed or Refractory GD2 Positive Solid Cancers
GermanyStudy Comparing MK-2870 and Pembrolizumab with Chemotherapy for Patients with Advanced Hormone Receptor Positive Breast Cancer
BelgiumStudy of Sacituzumab Tirumotecan and Pembrolizumab for Patients with Triple-Negative Breast Cancer Post-Surgery
AustriaStudy of Lenvatinib, Pembrolizumab, and Chemotherapy Combination for Patients with Advanced Esophageal Cancer Previously Treated with PD-1/PD-L1 Therapy
GermanyStudy on the Safety and Effectiveness of MK-2870 Alone or with Other Drugs for Patients with Colorectal, Pancreatic, and Biliary Tract Cancers
ItalyStudy of dapirolizumab pegol placental transfer to infants in pregnant women with active systemic lupus erythematosus (drug combination)
AustriaStudy of melpida with drug combination in patients with Hereditary Spastic Paraplegia Type 50 (SPG50)
SpainOM336 for Desensitization in Patients with End-Stage Renal Failure Awaiting Kidney Transplantation
AustriaStudy of tarlatamab and durvalumab compared to durvalumab alone for patients with extensive stage small cell lung cancer
AustriaSacituzumab Tirumotecan in Recurrent or Metastatic Cervical Cancer After Platinum Chemotherapy and Anti-PD-L1 or Anti-PD-1 Therapy
AustriaLong-term safety study of NNC6019-0001 for patients with transthyretin amyloid cardiomyopathy (ATTR-CM)
CzechiaStudy of ifinatamab deruxtecan alone or in combination with other treatments for patients with metastatic castration-resistant prostate cancer
FranceTell us about your condition – we search every trial in Europe and connect you with the right site.
